

Environmental Carcinogens and Risk for Human Liver Cancer

2

John D. Groopman

Contents

2.1 Introduction.....	25
2.2 Molecular Biomarkers for Environmental Carcinogens..	25
2.3 Environmental Etiology of HCC	27
2.4 Methods for Biomarker Measurement.....	27
2.5 Validation of Biomarkers of Environmental Carcinogens	29
2.6 Biomarkers in Human Investigations.....	30
2.7 Intervention Trials Using Aflatoxin Biomarkers	33
2.8 DNA Mutations Measured in Human Plasma and HCC	35
2.9 Summary	35
References	36

2.1 Introduction

Collectively, liver cancer, including hepatocellular carcinoma (HCC) and cholangiocarcinoma, accounts for 9.1 % of all reported cancer deaths and is the second most common cause of cancer mortality worldwide [1]. The incidence of liver cancer varies enormously globally and unfortunately the burden of this nearly always fatal disease is much greater in the less economically developed countries of Asia and sub-Saharan Africa (Fig. 2.1) [2]. HCC is also the most rapidly rising solid tumor in the US and Central America and is overrepresented in minority communities, including African-Americans, Hispanic/Latino-Americans, and Asian-Americans [1, 3, 4]. Overall, there are more than 750,000 new cases each year and more than 300,000 deaths annually in the People's Republic of China (PRC.) alone [2]. In contrast with most common cancers in the economically developed world where over 90 % of cases are diagnosed after the age of 45, in high-risk regions for liver cancer onset begins to occur in both men and women by 20 years of age and peaks between 40–49 years of age in men and between 50–59 years of age in women [5–7]. This earlier onset of HCC might be attributable to exposures that are both substantial and persistent across the life span. Gender differences in liver cancer incidence have also been well described and worldwide the number of cases among men were 554,000 and 228,000 among women in 2012 [8]. These epidemiologic findings are also reflected in experimental animal data for one potent liver carcinogen linked to human HCC, aflatoxin, where male rats have been found to have an earlier onset and higher incidence of cancer compared to female animals [9]. Thus, the consistency of the experimental animal and human data points to the important role that, environmental exposures play in gender differences in HCC risk.

This chapter will review the significant data that links exposures to specific environmental carcinogens and the development of HCC in many parts of the world. These epidemiologic studies have been made possible by devising

J.D. Groopman (✉)
Department of Environmental Health Sciences, Bloomberg School
of Public Health, Johns Hopkins University, 615 North Wolfe
Street, Baltimore, MD 21205, USA
e-mail: jgroopm1@jhu.edu




Fig. 2.1 Age-standardized mortality of liver cancer in men and women worldwide [13, 165]

biomarkers reflective of exposure and risk. The translation of these basic science findings to an understanding of the etiology of HCC has also provided guidance for the development of preventive interventions in high-risk populations. We will review a number of these major investigations to provide an overview of this very active field of research.

2.2 Molecular Biomarkers for Environmental Carcinogens

Molecular biomarkers are typically used as indicators of exposure, effect, or susceptibility for both individuals and populations. A biomarker of exposure refers to measurement of the specific compound of interest, its metabolite(s), or its specific interactive products in a body compartment or fluid, which indicates the presence and magnitude of current and past exposure. A biomarker of effect indicates the presence and magnitude of a biological response from exposure to an environmental agent. Such a biomarker may be an endogenous component, a measure of the functional capacity of the system, or an altered state recognized as impairment or disease. A biomarker of susceptibility is an indicator or a metric of an inherent or acquired ability of an individual to respond to the challenge of exposure to a specific toxicant. Such a biomarker may be the unusual presence or absence of an endogenous component, or an abnormal functional response to an administered challenge [10]. Measures of

these biomarkers through molecular epidemiology studies have great utility in addressing the relationships between exposure to environmental agents and development of clinical diseases, and in identifying those individuals at high risk for the disease. The aflatoxin/liver cancer work is an exemplar of this strategy [11]. These data also help to inform the risk assessment process, where the effectiveness of regulations and policy can be tested against biological measurements of exposure and effect.

The validation of any biomarker-effect link requires parallel experimental and human studies [12]. Following the development of a hypothesis of an exposure disease linkage, there is the need to devise the analytical methodology necessary to measure these biological markers in human and experimental samples. Conceptually, an appropriate animal model is often used to determine the associative or causal role of the biomarker in the disease or effect pathway, and to establish relations between dose and response. The putative biomarker can be validated in pilot human studies, where sensitivity, specificity, accuracy, and reliability parameters can be established. Data obtained in these studies can then be extended to assess intra- or interindividual variability, background levels, relationship of the biomarker to external dose or to disease status, as well as feasibility for use in larger population-based studies. To fully interpret the information that the biomarker provides, prospective epidemiological studies may be necessary to demonstrate the role that the biomarker plays in the overall pathogenesis of

the disease or effect. Ultimately, these biomarkers can be translated as intermediate endpoints in interventions in both experimental models and high-risk human populations to optimize agent selection, dose and schedule, and other parameters influencing efficacy.

2.3 Environmental Etiology of HCC

As described above, HCC is among the leading causes of cancer death in most parts of the economically developing world. The unequal distribution of this disease is depicted by the map in Fig. 2.1 drawn from the IARC cancer data [1, 8, 13]. Since the burden of HCC is also coincident with regions where aflatoxin exposure is high, many efforts that started over 40 years ago examined this possible association [14]. These initial studies were hindered by the lack of adequate data on aflatoxin intake, excretion and metabolism in people, the underlying susceptibility factors such as diet and viral exposure, as well as by the incomplete statistics on worldwide cancer morbidity and mortality. Despite these deficiencies, early studies did provide data illustrating that increasing HCC rates corresponded to increasing levels of dietary aflatoxin exposure [15]. The commodities most often found to be contaminated by aflatoxin were common human food staples including peanuts, cottonseed, corn, and rice [16]. The requirements for aflatoxin production are relatively nonspecific since molds can produce these toxins on almost any foodstuff and the final levels in the grain product can vary from micrograms to tens of milligrams [17]. Indeed, in a case of aflatoxin-related deaths in rural villages in Kenya, daily exposures were estimated to be over 50 mg [18]. Because contamination of foodstuffs is so heterogeneous, the measurement of human exposure to aflatoxin by sampling foodstuffs or by dietary questionnaires is extremely imprecise [19]. The development and validation of specific aflatoxin biomarkers represent a significant advance for accurate assessment of exposure in biofluids such as urine and blood.

Concurrent with the early aflatoxin research were a series of studies describing a role for the hepatitis B virus (HBV) in HCC pathogenesis. A number of investigations found that chronic carriers of HBV, as indicated by sequential hepatitis B surface antigen (HBsAg) positivity at six month intervals, were at increased risk of developing HCC [2, 20]. Further, the age of initial infection was directly related to development of the chronic carrier state and subsequent risk for HCC. Approximately 90 % of HBV infections acquired in infancy or early childhood become chronic, whereas only 10 % of infections acquired in adulthood become chronic, and less than 50 % of chronic carriers progress to HCC [21–24]. The global burden of HBV infection varies widely and China, Southeast Asia, and sub-Saharan Africa have some of the highest rates of chronic HBV infection in the world, with

prevalence of over 10 % [25]. The public health significance of HBV as a risk factor for HCC is staggering with the consideration that there are over 400 million viral carriers and between 10–25 % of these individuals are likely to develop HCC [22, 26, 27]. The biology, mode of transmission, and epidemiology of this viral infection continues to be actively investigated and has been recently reviewed [25, 26, 28].

To date, the significant etiological factors associated with development of HCC in the economically developing world are infection in early life with HBV and lifetime exposure to high levels of aflatoxin B₁ (AFB₁) in the diet [29, 30]. Indeed, the multiplicative interaction between HBV and AFB₁ has been documented in two separate cohorts at high risk for HCC [31–33]. Over the past 25 years, an appreciation for the role of the hepatitis C virus (HCV) has also emerged. HCV is contributing to HCC being the most rapidly rising solid tumor in the US and Japan [34]. Detailed knowledge of the etiology of HCC has spurred many mechanistic studies to understand the pathogenesis of this nearly always fatal disease [29, 35, 36]. Fortunately, the successful development and deployment of some highly effective new drugs that cure HCV infection is a major advance and will hopefully diminish the role of this virus in liver cancer [37, 38].

A number of other environmental exposures have been epidemiologically associated with HCC [39]. Vinyl chloride exposure in occupational settings has been associated with the onset of HCC in workers and there are the classic studies associating vinyl chloride exposure with angiosarcomas in the liver [40–42]. Studies have reported a multiplicative interaction between vinyl chloride exposure in the workplace and alcohol consumption in the enhancement of HCC [43]. Finally, a synergistic interaction between vinyl chloride workplace exposure and HBV status has been reported in a cohort in Taiwan [44].

Alcohol is a recognized human carcinogen and has been causally linked to HCC. Alcoholic cirrhosis and heavy alcohol use have been repeatedly associated with an increase in HCC risk [45]. However, it is unclear if alcohol use in the absence of cirrhosis influences HCC development [46]. Several studies have demonstrated an increased risk of HCC up to fivefold with consumption of more than 80 g of alcohol per day or approximately 6–7 drinks per day [45]. The risk of HCC ranges from borderline significant to doubled with chronic alcohol consumption of less than 80 g/day [45]. A synergism between alcohol, and HBV and HCV infections has also been described [45, 47].

Cigarette smoke is a recognized human carcinogen; however, a causal role in HCC is unclear [48]. For example, a hospital-based case-control study in Italy found no independent effect for tobacco and HCC risk [49]. However, a composite analysis of tobacco exposure and cancer risk

consistently shows a risk for liver cancer and smoking [2, 50]. Finally, the role of hormones in the development of HCC is unclear; however, in some studies, an increase risk of HCC was observed among users of oral contraceptives [51–53]. Collectively, these hormonal-related increases in HCC are only seen in low incident countries, where exposures to the other major risk factors for this cancer are rare.

In addition to the association of alcohol and HCC, in economically developed countries the dramatic rise in overweight and nonalcoholic fatty liver disease has also been related to increased HCC [54–56]. Of major concern for the future are the role that obesity, diabetes, and general underlying fatty liver disease will play in the development of liver cancer [57–59]. While the historic risk factors for liver cancer described above are addressed through a spectrum of prevention methods, these new etiologic factors portend an increasing trajectory in the incidence of this disease. Both

therapeutic and pre-disease interventions will need to be deployed now to blunt the impact of these risk factors in the decades to come.

2.4 Methods for Biomarker Measurement

In the case of AFB₁, the measurement of the DNA and protein adducts are of major interest because they are direct products of (or surrogate markers for) damage to a critical cellular macromolecular target. The chemical structures and metabolic pathways leading to the formation of the major aflatoxin macromolecular DNA and protein adducts were known (Fig. 2.2) [14, 60, 61]. The finding that the major aflatoxin–nucleic acid adduct AFB₁-N⁷-Gua excreted exclusively in urine of exposed rats spurred interest in using this metabolite as a biomarker of both exposure and risk.




Fig. 2.2 Structures of aflatoxin biomarkers

This adduct; however, has a short half life in the body (~ 8 h) [62]. The serum aflatoxin–albumin adduct was also examined as a biomarker since the longer half life of albumin (~ 3 weeks) integrates exposures over longer time periods. Studies in experimental models found that the formation of aflatoxin–DNA adducts in liver, excretion of the urinary aflatoxin–nucleic acid adduct, and formation of the serum albumin adduct were highly correlated [63].

Many different analytical methods are available for quantitation of chemical adducts in biological samples [64–66]. Each methodology has unique specificity and sensitivity and, depending on the application, the user can choose which is most appropriate. For example, to measure a single aflatoxin metabolite, a chromatographic method can resolve mixtures of aflatoxins into individual compounds, providing that the extraction procedure does not introduce large amounts of interfering chemicals. Antibody-based methods often are more sensitive than chromatography, but immunoassays are less selective because the antibody may cross-react with multiple metabolites. An interlaboratory collaboration used identical serum sample sets to analyze for aflatoxin–albumin adducts by ELISA, high-performance liquid chromatography (HPLC) with fluorescence detection (HPLC-f), and HPLC with isotope dilution mass spectrometry (IDMS). Overall, this study showed an excellent correlation between these three independent methodologies conducted in different laboratories [67].

An immunoaffinity clean-up/HPLC procedure was developed to isolate and measure aflatoxin metabolites in biological samples [68–70]. With this approach, we performed initial validation studies for the dose-dependent excretion of urinary aflatoxin biomarkers in rats after a single exposure to AFB₁ [71]. A linear relationship was found between AFB₁ dose and excretion of the AFB-N⁷-Gua adduct in urine over the initial 24 h period of exposure. In contrast, excretion of other oxidative metabolites, such as AFP₁ showed no linear association with dose. Subsequent studies in rodents that assessed the formation of aflatoxin macromolecular adducts after chronic administration also supported the use of DNA and protein adducts as molecular measures of exposure [72, 73]. Studies using isotope dilution mass spectrometry with liquid chromatography separation have demonstrated an increase in sensitivity of at least 1000-fold over technologies used for the detection of aflatoxin biomarkers 15 years ago [74–76]. Further, repeated analysis of serum collected in 1983 from aflatoxin-exposed people has demonstrated that the aflatoxin–lysine adduct in albumin is stable under a range of temperature storage conditions [77].

An area of considerable importance, that has received far less attention than it should, has been in the area of internal standard development. All quantitative measurements require the use of an internal standard to account for sample

to sample variations in the analyte recoveries. In the case of mass spectrometry, internal standards generally employ an isotopically labeled material that is identical to the chemical being measured. Obtaining such isotopically labeled materials requires chemical synthesis, if they are not commercially available, and has impeded the application of internal standards in many studies. In the case of immunoassays, internal standards pose a different challenge since the addition of an internal standard that is recognized by an antibody results in a positive value contribution. The dynamic range is usually less than 100 in immunoassays, and therefore great care must be taken to spike a sample with an internal standard so one can obtain a valid result. In contrast, most chromatographic methods result in dynamic ranges of analyses that can be over a 10,000-fold range of levels. The mass spectrometry methods are not only applicable for the quantitation of small molecules such as aflatoxin, but it has also been extended for use to measure mutations in DNA fragments found circulating in plasma that are mechanistically linked to the etiopathogenesis of HCC, such as p53 [78–81].

2.5 Validation of Biomarkers of Environmental Carcinogens

Over the past several decades, studies to identify effective chemoprevention strategies for aflatoxin carcinogenesis have been explored. The hypothesis was that reduction of aflatoxin–DNA and other macromolecular adduct levels by chemopreventive agents would be mechanistically related to and therefore predictive of cancer preventive efficacy. Initial data with a variety of established chemopreventive agents demonstrated that after a single dose of aflatoxin, levels of DNA adducts were reduced [82]. A more comprehensive study using multiple doses of aflatoxin and the chemopreventive agent ethoxyquin was carried out to examine the relationships between levels and rates of DNA adduct formation and removal and hepatic tumorigenesis in rats. Three months after aflatoxin treatment, it was observed that cotreatment with ethoxyquin had reduced both area and volume of liver occupied by presumptive preneoplastic foci by >95 %. This same protocol also dramatically reduced binding of AFB₁ to hepatic DNA, from 90 % initially to 70 % over the course of a 2 week carcinogen dosing period [72].

The experiment was then repeated with several different chemopreventive agents and in all cases aflatoxin-derived DNA and protein adducts were reduced; however, even under optimal conditions, the reduction in the macromolecular adducts always underrepresented the magnitude of the diminution in tumor burden [83, 84]. These macromolecular adducts can track with disease outcome on a population

basis, but in the multistage process of cancer the absolute level of adduct provides only a necessary but insufficient measure of tumor formation.

Experimental validation of the role of human HBV in HCC etiopathogenesis has been compromised by the very restricted nature of the number of species that can become infected with this virus. The chimpanzee and tree shrew can be infected by human HBV but neither has proven to be a cost-effective model for extensive investigation, while the woodchuck and duck can be infected with similar yet distinct HBV strains [85–87]. Transgenic mouse models have also been developed that generate a 100 % probability of developing HCC [88]. These transgenic mice have been used to explore the interaction of the HBV transgene with AFB₁ [89]. Collectively, these models are extremely valuable for the study of the underlying molecular pathways in the virally induced cancers but they have to date been of limited value in recapitulating the more complex etiology of human HCC.

Using the chemopreventive agent oltipraz, Roebuck et al. [83] established correlations between reductions in levels of AFB₁-N⁷-Gua excreted in urine and incidence of HCC in aflatoxin-exposed rats. Overall, reduction in biomarker levels reflected protection against carcinogenesis, but these studies did not address the quantitative relationship between biomarker levels and individual risk. Thus, in a follow-up study, rats dosed with AFB₁ daily for 5 weeks were randomized into three groups: no intervention; delayed-transient intervention with oltipraz during weeks 2 and 3 of exposure; persistent intervention with oltipraz for all 5 weeks of dosing [90]. Serial blood samples were collected from each animal and the integrated level of aflatoxin–albumin adducts over the exposure period decreased 20 and 39 % in the delayed transient and persistent oltipraz intervention groups, respectively, as compared with no intervention. Similarly, the total incidence of HCC dropped significantly from 83 to 60 % and 48 % in these groups. Overall, there was a significant association between integrated biomarker level and risk of HCC. When the predictive value of aflatoxin–serum albumin adducts was assessed within treatment groups, however, there was no association between integrated biomarker levels and risk of HCC. These data clearly demonstrated that levels of the aflatoxin–albumin adducts could predict population-based changes in disease risk, but had no power to identify individuals destined to develop HCC. Because of the multistage process of carcinogenesis, in order to determine individual risk of disease, a panel of biomarkers reflecting different stages will be needed.

In the most recent investigation, the synthetic oleanane triterpenoid 1-[2-cyano-3-12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im), a powerful activator of Keap1-Nrf2 signaling, was found to protect against AFB₁-induced


HCC. A lifetime cancer bioassay was undertaken in F344 rats dosed with AFB₁ (200 µg/kg rat/day) for 4 weeks and receiving either vehicle or CDDO-Im (three times weekly), one week prior to and throughout the exposure period. CDDO-Im completely protected (0/20) against AFB₁-induced liver cancer at 2 years of age compared to a 96 % incidence (22/23) observed in the AFB₁ group. With CDDO-Im treatment, integrated level of urinary AFB₁-N⁷-guanine was significantly reduced (66 %) and aflatoxin-N-acetylcysteine, a detoxication product, was consistently elevated (300 %) after the first AFB₁ dose. The remarkable efficacy of CDDO-Im as an anticarcinogen is established even in the face of a significant aflatoxin adduct burden. Consequently, the absence of cancer requires a concept of a threshold for DNA damage for cancer development [91].

2.6 Biomarkers in Human Investigations

Extensive cross-sectional epidemiologic studies have been conducted in high-risk groups for HCC, this concept is diagramed in Fig. 2.3. The HBV biomarkers were developed and validated using the HBsAg biomarker. This work directly led to the research that resulted in a vaccine effective against HBV. Indeed, this vaccine has been reported to reduce HCC in a cohort of young children in Taiwan [92]. Further, the serology of HBV has been extensively described and developed [28]. The work on AFB₁ exposures and its role in HCC etiology has taken a far longer time period to come to fruition. Initial studies in the Philippines [93] demonstrated that an oxidative metabolite of aflatoxin could be measured in urine and thus had potential to serve as an internal dose marker. Subsequent work conducted in the People's Republic of China and The Gambia, West Africa, determined that the levels of urinary aflatoxin biomarkers showed dose-dependent relationships with aflatoxin intake. Gan et al. [94] and Wild et al. [95] also monitored levels of aflatoxin–serum albumin adducts and observed a highly significant association between intake of aflatoxin and level of adduct.

Biomarker development in HCC has been further advanced by the molecular biological studies on the TP53 tumor suppressor gene, the most common mutated gene detected in human cancer [96, 97]. Many studies of *p53* mutations in HCC occurring in populations exposed to high levels of dietary aflatoxin have found high frequencies of guanine to thymine transversions, with clustering at codon 249 [98, 99]. In contrast, no mutations at codon 249 were found in *p53* in HCC from Japan and other areas where there was little exposure to aflatoxin [100, 101]. The occurrence of this specific mutation has been mechanistically associated with AFB₁ exposure in experimental models including bacteria [102] and through demonstration that

Fig. 2.3 Mechanistic-based biomarkers of aflatoxin and HBV



aflatoxin-8,9-epoxide could bind to codon 249 of *p53* in a DNA plasmid in vitro [103]. Mutational analysis of the *p53* gene in human HepG2 cells and hepatocytes exposed to AFB₁ found preferential induction of the transversion of guanine to thymine in the third position of codon 249 [104] [105, 106]. In summary, studies of the prevalence of codon 249 mutations in HCC cases from patients in areas of high or low exposure to aflatoxin suggest that a G-T transition at the third base is associated with aflatoxin exposure and in vitro and mutagenesis data would seem to support this hypothesis [107].

Although useful, cross-sectional epidemiological studies have limited power to relate an exposure to disease outcome since these studies only provide a view during a short time frame. Data from the cross-sectional aflatoxin biomarker studies demonstrated short-term dose-response effects for a number of the aflatoxin metabolites, including the major nucleic acid adduct, serum albumin adduct, and AFM₁. This information could then be used in follow-up studies to test a number of hypotheses about risk to individuals having high exposures, the efficacy of exposure remediation and interventions and mechanisms underlying susceptibility.

Longitudinal studies are extremely important in the development and validation process for biomarkers. These investigations permit an understanding of the stability in storage and the tracking potential of each biomarker, which are essential for the evaluation of the predictive power of the biomarker. While long-term stability of many of the HBV markers have been well-established [108], we needed to know whether the aflatoxin metabolites were stable over the long term. Aflatoxin-albumin adducts, as described above,

in human sera were found to be stable for at least 25 years when stored at -20°C [77].

An objective in development of any biomarker is to use them as predictors of past and future exposure status in people. This concept is embodied in the principle of tracking, which is an index of how well an individual's biomarker remains positioned in a rank order relative to other individuals in a group over time. Tracking within a group of individuals is expressed by the intraclass correlation coefficient. When the intraclass correlation coefficient is 1.0, a person's relative position, independent of exposure, within the group does not change over time. If the intraclass correlation coefficient is 0.0, there is random positioning of the individual's biomarker level relative to the others in the group throughout the time period. The tracking concept is central to interpreting data related to exposure and biomarker levels and requires acquisition of repeated samples from subjects. Unfortunately, data on the temporal patterns of formation and persistence of aflatoxin macromolecular adducts in human samples are very limited. Obviously, chemical-specific biomarkers measured in cross-sectional studies cannot provide information on the predictive value or tracking of an individual's marker level over time. In contrast to the aflatoxin situation, the HBV biomarker tracking has been well characterized and forms the basis for defining chronic infection status [108].

Tracking is important in assessing exposure and this information is essential in the design of intervention studies. In all these situations, it is critical to know how many biomarker samples are required and when they should be obtained. For example, if exposure remains constant and the

tracking value for a marker changes over time, it might be assumed that the change in tracking is due to a biological process, such as an alteration in the balance of metabolic pathways responsible for adduct formation. On the other hand, lack of tracking can be attributable to great variance in exposure. Therefore, to determine unequivocally the contributions of intra- and interindividual variations to biomarker levels, experiments must assess tracking over time.

Many published case-control studies have examined the relation of aflatoxin exposure and HCC. Compared with cohort studies, case-control studies are both cost- and time-effective. Unfortunately, case-control studies are often initiated long after exposure has occurred and it cannot be assumed that the exposure has not appreciably changed over time. Also, such studies involve assumptions in the selection of controls, including that the disease state does not alter metabolism of aflatoxin. Thus, matching of cases and controls in a specific biomarker study is much more difficult than in a case-control study involving genetic markers [14].

Data obtained from cohort studies have the greatest power to determine a true relationship between an exposure and disease outcome because one starts with a healthy cohort, obtains biomarker samples, and then follows the cohort until significant numbers of cases are obtained. A nested study within the cohort can then be designed to match cases and controls. An advantage of this method is that causation can be established (due to the longitudinal nature of cohort studies, there is no temporal ambiguity) and selection bias is minimized. A major disadvantage, however, is the time needed in follow-up (often years) to accrue the cases, especially for chronic diseases such as HCC. This disadvantage can be overcome in part by enrolling large numbers of people (often tens of thousands) to ensure case accrual at a reasonable rate.

Two major cohort studies with aflatoxin biomarkers have demonstrated the important role of this carcinogen in the etiology of HCC. The first study, comprising more than 18,000 men in Shanghai, examined the interaction of HBV and aflatoxin biomarkers as independent and interactive risk factors for HCC. The nested case-control data revealed a statistically significant increase in the adjusted relative risk (RR) of 3.4 [95 % CI: 1.1–10.0] for those HCC cases where urinary aflatoxin biomarkers were detected. For HBsAg-positive people only the RR was 7 [95 % CI: 2.2–22.4], but for individuals with both urinary aflatoxins and positive HBsAg status the RR was 59 [95 % CI: 16.6–212.0] [31, 32]. These results strongly support a causal relationship between the presence of the chemical and viral-specific biomarkers and the risk of HCC.

Subsequent cohort studies in Taiwan have substantially confirmed the results from the Shanghai investigation. Wang et al. [33] examined HCC cases and controls nested within a cohort and found that in HBV-infected people there was an

adjusted odds ratio (OR) of 2.8 for detectable compared with nondetectable aflatoxin–albumin adducts and 5.5 for high compared with low levels of aflatoxin metabolites in urine. In a follow-up study, there was a dose–response relationship between urinary AFM₁ levels and risk of HCC in chronic HBV carriers. Similar to the Shanghai study, the HCC risk associated with AFB₁ exposure was more striking among the HBV carriers with detectable AFB₁-N⁷-gua in urine.

Many studies across the globe have explored the relationship between HBV infection and HCC and the risk estimates range from 3 to 30 in case-control studies and from 5 to 148 in cohort studies [52]. In the nested case-control study cited above, the risk of HCC was 7.3 times higher among HBsAg-positive individuals compared to HBsAg-negative individuals, controlled for smoking and aflatoxin exposures [32]. A small hospital-based case-control study from Northeast Thailand showed an adjusted OR of 15.2 for the presence of HBsAg among HCC patients [109]. An adjusted OR of 13.5 was reported from a case-control study in The Gambia [25]. The risk of HCC among HBsAg-positive individuals in Korea from a prospective cohort study of government workers, was 24.3 among men and 54.4 among women, adjusted for age, smoking, alcohol use, and diabetes [110]. A similar prospective study from Taiwan found men positive for HBsAg were 223 times more likely to develop HCC than men HBsAg negative [23].

The contribution of HBV to the pathogenesis of liver cancer is multifactorial and is complicated by the identification of mutant variants in HBV that modulate the carcinogenesis process [111, 112]. The HBV genome encodes its essential genes with overlapping open-reading frames; therefore, a mutation in the HBV genome can alter the expression of multiple proteins. In many cases of HCC in China and Africa a double mutation in the HBV genome, an adenine to thymine transversion at nucleotide 1762, and a guanine to adenine transition at nucleotide 1764 (1762^T/1764^A) has been found in tumors [113–115]. This segment of the HBV genome contains an overlapping sequence for the base core promoter and the HBV X gene; therefore, the double mutation in codon 130 and 131 of the HBV X gene reported in human HCC is identical to the 1762 and 1764 nucleotide changes [116]. The increasing occurrence of these mutations have been also associated with the increasing severity of the HBV infection and cirrhosis [114, 115]. This acquired mutation following HBV integration into hepatocytes was originally characterized in HBV e antigen negative people [117]. The 1762^T/1764^A double mutation occurs more frequently in people infected with the genotype C strains of HBV, which is the most common genotype found in East Asian patients [118–120]. This double mutation tracks with an increased inflammatory response that becomes stronger as the progression of liver damage transits through chronic hepatitis and into a cirrhosis stage [121].

The underlying mechanism of the effects of HBV e antigen on the biology of inflammation and cirrhosis are still unclear, but there are substantial data that point to modulation of the immune surveillance system and immune tolerance in the presence and absence of this protein [121–123]. The 1762^T/1764^A double mutation has also been demonstrated to affect an increase in the rate of HBV genome synthesis in cellular models [111, 112]. In cellular studies, the 1762^T/1764^A double mutation increased the replication of the viral genome twofold and in the case of some of rarer triple mutations, an eightfold increase in genome replication was found [111, 123]. Recent data have also shown that there is a sequential accumulation of these mutations in people during the course of the progression to cancer [124].

Recently, a matched case-control investigation of 345 men who died of HCC and 625 controls were nested within a cohort of male HBsAg carriers from Qidong, China. Matched preserving odds ratios (ORs) were used as a measure of association and 95 % confidence intervals (CIs) as a measure of precision. A total of 278 (81 %) of the cases were positive for the HBV 1762^T/1764^A mutation compared with 250 (40 %) of the controls. The matched preserving OR of 6.72 (95 % CI: 4.66–9.68) strongly indicated that cases were significantly more probably than controls to have the mutation. Plasma levels of DNA harboring the HBV mutation were on average 15-fold higher in cases compared with controls ($P < 0.001$). Most strikingly, the level of the mutation in the 20 controls which later developed and died of HCC were on average 274-fold higher than controls which did not develop HCC. Thus, within this cohort of HBsAg carriers at high risk of developing HCC, individuals positive for the HBV 1762^T/1764^A mutation at enrollment were substantially more probably to subsequently develop HCC, with a higher concentration of the mutation in plasma enhancing predisposition for cancer development [125].

2.7 Intervention Trials Using Aflatoxin Biomarkers

Clinical trials and other interventions are designed to translate findings from human and experimental investigations to public health prevention. Both primary (to reduce exposure) and secondary (to alter metabolism and deposition) interventions can use specific biomarkers as endpoints of efficacy. Such biomarkers can be applied to the preselection of exposed individuals for study cohorts, thereby reducing study size requirements. They can also serve as short-term modifiable endpoints [126]. In a primary prevention trial, the goal is to reduce exposure to aflatoxins in the diet. Interventions can range from attempting to lower mold growth in harvested crops to using trapping agents that block the uptake of ingested aflatoxins. In secondary prevention trials,

one goal is to modulate the metabolism of ingested aflatoxin to enhance detoxification processes, thereby reducing formation of DNA adducts and enhancing elimination.

The use of aflatoxin biomarkers as efficacy endpoints in primary prevention trials in West Africa has been reported [127]. This study assessed postharvest measures to restrict aflatoxin contamination of groundnut crops. Six hundred people were monitored and in control villages mean aflatoxin–albumin concentration increased postharvest (from 5.5 pg/mg [95 % CI 4.7–6.1] immediately after harvest to 18.7 pg/mg [17.0–20.6] 5 months later). By contrast, mean aflatoxin–albumin concentration in intervention villages after 5 months of groundnut storage was much the same as that immediately postharvest (7.2 pg/mg [6.2–8.4] vs. 8.0 pg/mg [7.0–9.2]). At 5 months, mean adduct concentration in intervention villages was less than 50 % of that in control villages (8.0 pg/mg [7.2–9.2] vs. 18.7 pg/mg [17.0–20.6], $p < 0.0001$). Thus, primary prevention maybe an effective means to reduce HCC burden, especially in areas where single foodstuffs such a groundnuts are major components of the diet.

Chemoprevention is another strategy for the secondary prevention of cancer. This approach entails the use of drugs, dietary supplements or functional foods to retard, block, or reverse the carcinogenic process. These strategies serve to alter cell fate, by either preventing cells from acquiring carcinogenic genetic damage or by impeding proliferation of preneoplastic cells or, alternatively, accelerating their apoptosis. One successful strategy for cancer chemoprevention is modulation of drug-metabolizing enzymes, leading to facilitated inactivation or elimination of endogenous and environmental carcinogens. Inducers of conjugating enzymes such as dithiolethiones and sulforaphane inhibit tumorigenesis of environmental carcinogens in various animal models [83, 128]. Increasing lines of evidence show that the Keap1-Nrf2 complex is a key molecular target of these chemopreventive enzyme inducers. The transcription factor Nrf2 is a member of the basic leucine-zipper NF-E2 family and interacts with the antioxidant response element (ARE) in the promoter region of detoxifying enzymes. A cytoplasmic actin binding protein, Keap1, is an inhibitor of Nrf2 that sequesters it in the cytoplasm and facilitates its ubiquitination and subsequent degradation. Inducers disrupt this process, allowing Nrf2 to accumulate and translocate to the nucleus [129]. Experimental disruption of the *Nrf2* gene in mice leads to enhanced sensitivity to carcinogens and the loss of chemopreventive efficacy by inducers [130, 131].

1,2-Dithiole-3-thiones were reported in the 1950s to be constituents of cruciferous vegetables in Czechoslovakia [132], although a more recent study failed to find the unsubstituted 3*H*-1,2-dithiole-3-thione in cabbage in the United States [133]. Oltipraz, a substituted 1,2-dithiole-3-thione, was originally developed by the pharmaceutical

industry as a possible treatment for schistosomiasis and was extensively evaluated in clinical trials in the early 1980s. In extensive preclinical evaluation by the National Cancer Institute and others, oltipraz was found to be effective as an anticarcinogen in nearly a score of animal models [134].

Aflatoxin biomarkers (Fig. 2.2) were used as intermediate endpoints in a Phase IIa liver cancer chemoprevention trial of oltipraz in Qidong, People's Republic of China [135, 136]. This was a placebo-controlled, double-blind study in which participants were randomized to receive placebo or 125 mg oltipraz daily or 500 mg oltipraz weekly. Urinary aflatoxin M₁ levels were reduced by 51 % compared with the placebo group in persons receiving the 500 mg weekly dose. No significant differences were seen in urinary aflatoxin M₁ levels in the 125-mg group compared with placebo. This effect was thought to be due to inhibition of cytochrome P450 1A2 activity. Median levels of aflatoxin–mercapturic acid (a glutathione conjugate derivative) were elevated six-fold in the 125-mg group, but were unchanged in the 500-mg group. Increased formation of aflatoxin–mercapturic acid reflects induction of aflatoxin conjugation through the actions of glutathione-S-transferases (GSTs). The apparent lack of induction in the 500-mg group was thought to reflect masking caused by diminished aflatoxin-8,9-epoxide formation for conjugation through the inhibition of CYP1A2 seen in this group. This initial study demonstrated for the first time that aflatoxin biomarkers could be modulated in humans in a manner that would predict decreased disease risk.

Although the oltipraz clinical trial demonstrated the proof of principle for increasing pathways leading to aflatoxin detoxication in humans, the practicality of using a drug-based method for prevention in the economically developing world is limited. Not only is there a potential for adverse health effects from any long-term exposure to a drug, but also the expense of this type of intervention may make the intervention cost-prohibitive for these populations. There may also be culture-based aversion to the use of drugs. Fortunately, oltipraz is not the only agent that affects enzyme changes through the Nrf2-Keap1 pathway. Sulforaphane has been extensively examined for its chemopreventive properties and is a potent activator of the Nrf2-Keap1 pathway leading to increased expression of carcinogen detoxifying enzymes [131, 137]. Many foods have high levels of these enzyme inducers [138, 139]. In a recent chemoprevention trial in humans, a beverage formed from hot water infusions of 3-day-old broccoli sprouts, containing defined concentrations of glucosinolates (a stable precursor of the anticarcinogen sulforaphane), was evaluated for its ability to alter the metabolic disposition of aflatoxin. In this study, 200 healthy adults drank infusions containing either 400 or <3 μ mole glucoraphanin nightly for 2 weeks. Urinary levels of aflatoxin-*N*⁷-guanine were similar in individuals in the two

intervention arms. However, measurement of urinary levels of dithiocarbamates (sulforaphane metabolites) indicated striking interindividual differences in bioavailability. This outcome may reflect individual differences in the rates of hydrolysis of glucoraphanin to sulforaphane by the intestinal microflora of the study participants. Accounting for this variability, a significant inverse association was observed for excretion of dithiocarbamates and aflatoxin-*N*⁷-guanine adducts in individuals receiving broccoli sprout glucosinolates [140]. This preliminary study illustrates the potential use of an inexpensive, easily implemented, food-based method for secondary prevention in a population at high risk for aflatoxin exposures. A follow-up intervention designed to minimize the interindividual variability in the pharmacokinetics of the glucoraphanin precursor is currently in progress.

Many studies have demonstrated that green tea polyphenols (GTP) inhibit various chemically induced cancers in experimental animals, and epidemiological studies also point to the potential benefit of these compounds [141, 142]. Qin et al. [143] studied the effects of GTP in drinking water for two or four weeks to protect against the development of AFB₁-induced hepatocarcinogenesis in the rat. Results revealed that aflatoxin–DNA binding in the liver was significantly (20–30 %) inhibited in animals pretreated with green tea and that the burden of preneoplastic lesions was also significantly inhibited by 60–70 %. The experimental data on GTP provided the impetus to translate this strategy to human clinical trials. In an initial study in an aflatoxin-exposed high-risk group in Guangxi, People's Republic of China, the effects of GTP was assessed by analysis of blood and urine samples collected from a randomized, double-blinded, placebo-controlled Phase IIa chemoprevention trial [144]. Blood serum of all participants contained aflatoxin–albumin adducts at the outset. They were then required to ingest capsules containing GTP at doses of 500 or 1000 mg, or a placebo daily for 3 months. Analyses were done on blood and urine samples collected during this period to evaluate the efficacy of GTPs in modulating aflatoxin biomarkers [145]. Levels of albumin adducts at baseline were comparable for all three dose groups and no significant differences were observed in adduct levels in the placebo group over the 3 month period. However, reductions in albumin adduct levels were observed in both groups receiving GTPs over the 3 month intervention period. An analysis using a mixed-effects model indicated that the reduction in aflatoxin–albumin adduct levels over time was dose- and time-dependent. Reductions in median aflatoxin M₁ levels, as compared with the placebo, were found in both GTP groups at 3 months of the intervention, while significant elevations in median aflatoxin–mercapturic acid levels were observed in both GTP groups compared with the placebo group at 1 and 3 months of intervention. These results

indicate that GTPs effectively modulate aflatoxin metabolism and metabolic activation, as had been previously observed with oltipraz in Qidong.

2.8 DNA Mutations Measured in Human Plasma and HCC

The development and validation of biomarkers for early detection of disease or for the identification of high-risk individuals is a major translational effort in cancer research. α -Fetoprotein is widely used as a HCC diagnostic marker in high-risk areas because of its ease of use and low cost [146]. However, this marker suffers from low specificity due to its occurrence in diseases other than liver cancer. Moreover, no survival advantage is seen in populations when α -fetoprotein is used in large-scale screening [147]. Such inadequacies have contributed to the need to identify other molecular biomarkers that are possibly more mechanistically associated with HCC development, including hypermethylation of the p16 gene, p15 gene, GSTP1 promoter regions and codon 249 mutations in the p53 gene [148–151]. Results from investigations of p16, p15, GSTP1 promoter hypermethylation and p53 mutations indicate that these markers are prevalent in HCC, but there is as of yet limited information on the temporality of these genetic changes prior to clinical diagnosis.

Several studies have now demonstrated that DNA isolated from serum and plasma of cancer patients contains the same genetic aberrations as DNA isolated from an individual's tumor [79, 152, 153]. The process by which tumor DNA is released into circulating blood is unclear but may result from accelerated necrosis, apoptosis, or other processes [154]. While the detection of specific p53 mutations in liver tumors has provided insight into the etiology of certain liver cancers, the application of these specific mutations to the early detection of cancer offers great promise for prevention [155]. In a seminal report, Kirk et al. [156] reported the detection of codon 249 p53 mutations in the plasma of liver tumor patients from The Gambia; however, the mutational status of the tumors were not known. These authors also reported a small number of cirrhosis patients having this mutation and given the strong relation between cirrhosis and future development of HCC, raised the possibility of this mutation being an early detection marker. Jackson et al. [79], used short oligonucleotide mass analysis (SOMA), in lieu of DNA sequencing for analysis of specific p53 mutations in HCC samples. Analysis of 20 plasma and tumor pairs showed 11 tumors containing the specific mutation, six of the paired plasma samples exhibited the same mutation.

The temporality of the detection of this mutation in plasma before and after the clinical diagnosis of HCC was

facilitated by the availability of longitudinally collected plasma samples from a cohort of 1638 high-risk individuals in Qidong, PRC., that have been followed since 1992 [157]. The results showed that in samples collected prior to liver cancer diagnosis, 21.7 % of the plasma samples had detectable levels of the codon 249 mutation. The persistence of this pre-diagnosis marker was borderline statistically significant. The codon 249 mutation in p53 was detected in 44.6 % of all plasma samples following the diagnosis of HCC. Collectively these data suggest that nearly one-half of the potential patients with this marker can be detected at least 1 year and in one case 5 years prior to diagnosis.


Using a novel internal standard plasmid, plasma concentrations of p53 codon 249-mutated DNA were quantified by SOMA in 89 HCC cases, 42 cirrhotic patients, and 131 nonliver diseased control subjects, all from highly aflatoxin-exposed regions of The Gambia [81]. The HCC cases had higher median plasma concentrations of the p53 mutation (2800 copies/mL; interquartile range: 500–11,000) compared with either cirrhotic (500 copies/mL; interquartile range: 500–2600) or control subjects (500 copies/mL; interquartile range: 500–2000). Levels of >10,000 copies of p 53 codon 249 mutation/mL plasma were also significantly associated with the diagnosis of HCC (OR, 15; 95 % confidence interval, 1.6–140) when compared with cirrhotic patients. Potential applications for the quantification of this alteration of DNA in plasma include estimation of long-term, cumulative aflatoxin exposure, and selection of appropriate high-risk individuals for targeted intervention.

2.9 Summary

HCC is a slowly developing process involving progressive genetic insults and their resulting genomic changes. The advances in modern DNA sequencing technologies have been used on a wide number of human liver cancers with a range of etiological factors that reveal a very complete picture of driver and passenger mutational changes in these tumors [158–160]. These data will hopefully form a foundation for new therapies and early detection screening methods. Further, as these sequencing methods become extended to characterize microRNAs and proteomic methods help characterize the molecular phenotype of liver cancers, these collective data will help define the preclinical period of tumor development. This will be very valuable for our mechanistic understanding of HCC up to 30 years after chronic infection with HBV, HCV and/or aflatoxin exposure prior to clinical diagnosis. These studies may also reveal insights into chronic hepatitis and cirrhosis since 70–75 % of all HCC is accompanied by cirrhosis [113, 158].

The molecular epidemiology investigations of aflatoxin, HBV, and HCC probably represent one of the most

Fig. 2.4 Range of aflatoxin exposure in different populations [162]



extensive data sets in the field of environmental carcinogenesis and this work serves as a template for future studies of the role of other environmental agents in human diseases with chronic, multifactorial etiologies. The development of these biomarkers has been based upon the knowledge of the biochemistry and toxicology of aflatoxins gleaned from both experimental and human studies. These biomarkers have subsequently been utilized in experimental models to provide data on the modulation of these markers under different situations of disease risk. This systematic approach provides encouragement for design and successful implementation of preventive interventions.

Recent data utilizing the cancer registry in Qidong, China has provided some very exciting insights into the role of aflatoxin in liver cancer. Utilizing the availability of serum samples collected over a 20-year period, aflatoxin exposure patterns have been documented. In China, major agricultural reforms in the 1980s led to diminished maize consumption, a major source of aflatoxin contamination. The population-based cancer registry in Qidong, China has documented a more than 50 % reduction in HCC mortality rates occurring across birth cohorts from the 1960s to the 1980s for Qidongese less than 35 years of age although all were born before universal vaccination of newborns. Median levels of the aflatoxin biomarker decreased from 19.3 pg/mg albumin in 1989 to undetectable (<0.5 pg/mg) by 2009. A population attributable benefit of 65 % for reduced PLC mortality was estimated from a government-facilitated switch of dietary staple from maize to rice; 83 % of this benefit was in those infected with HBV. Food policy reforms in China thus

resulted in a dramatic decrease in aflatoxin exposure, which, independent of HBV vaccination, reduced liver cancer risk. The extensive HBV vaccine coverage now in place augurs even greater risk reductions in the future [161].

Finally, in an attempt to place the extent of global exposures to aflatoxin across different populations, with varying health endpoints, we have determined the aflatoxin-albumin adduct levels shown in Fig. 2.4. These samples were from studies in Nepal, Bangladesh, Kenya during an acute toxic event and China [67, 161–163]. We note that a 1 µg per day exposure results in a 0.7 pg/mg albumin adduct level and this increases linearly using adduct formation data gleaned from human exposure studies [164]. Thus these findings provide for the first time a guidepost for relating daily exposure levels to acute and chronic disease outcomes and using biomarkers the efficacy of policy and regulation can be objectively measured.

Acknowledgments This work was supported in part by grants 5 P30 CA006973, R01 CA190610 and R35 CA197222 from the USPHS.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136:E359–86. doi:10.1002/ijc.29210 (Epub 2014 Oct 9).
2. World Cancer Report 2014: International Agency for Research on Cancer; 2014.

3. American Cancer Society Cancer Facts and Figures 2005. 2005:22–7.
4. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? *Hepatology*. 2014;60(5):1767–75. doi:10.1002/hep.27222 (Epub 2014 Aug 25). 2014:1767–75.
5. Chen JG, Zhu J, Parkin DM, Zhang YH, Lu JH, Zhu YR, et al. Trends in the incidence of cancer in Qidong, China, 1978–2002. *Int J Cancer*. 2006;119:1447–54.
6. Vatanasapt V, Martin N, Sriplung H, Chindavijak K, Sontipong S, Sriamporn S, et al. Cancer incidence in Thailand, 1988–1991. *Cancer Epidemiol Biomarkers Prev*. 1995;4:475–83.
7. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin*. 2005;55:74–108.
8. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015;65:87–108. doi:10.3322/caac.21262 (Epub 2015 Feb 4).
9. Wogan GN, Newberne PM. Dose-response characteristics of aflatoxin B1 carcinogenesis in the rat. *Cancer Res*. 1967;27:2370–6.
10. Wang JS, Links JM, Groopman JD. Molecular epidemiology and biomarkers. New York: Marcel Dekker; 2001.
11. Kensler TW, Roebuck BD, Wogan GN, Groopman JD. Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology. *Toxicol Sci*. 2011;120(Suppl 1):S28–48.
12. Groopman JD, Kensler TW. The light at the end of the tunnel for chemical-specific biomarkers: daylight or headlight? *Carcinogenesis*. 1999;20:1–11.
13. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancerbase no. 11 [Internet]. 2013.
14. Kensler TW, Roebuck BD, Wogan GN, Groopman JD. Aflatoxin: a 50 year odyssey of mechanistic and translational toxicology. *Toxicol Sci*. 2011;2010:3.
15. Bosch FX, Muñoz N. Review. Prospects for epidemiological studies on hepatocellular cancer as a model for assessing viral and chemical interactions. *IARC Sci Publ*. 1988;89:427–38.
16. Eaton DL, Groopman JD. The toxicology of aflatoxins: human health, veterinary and agricultural significance. San Diego, CA: Academic Press; 1994.
17. Ellis W, Smith JP, Simpson BK, Oldham JH. Aflatoxin in food: occurrence, biosynthesis, effects on organisms, detection and methods of control. *Crit Rev Food Sci Nutr*. 1991;30:403–39.
18. Probst C, Njapau H, Cotty PJ. Outbreak of an acute aflatoxicosis in Kenya in 2004: identification of the causal agent. *Appl Environ Microbiol*. 2007;73:2762–4.
19. Campbell AD, Whitaker TB, Pohland AE, Dickens JW, Park DL. Sampling, sample preparation, and sampling plans for foodstuffs for mycotoxin analysis. *Pure Appl Chem*. 1986;58:305–14.
20. Kew MC. Hepatology: a century of progress. *Clin Liver Dis*. 2000;4:257–68.
21. Hadziyannis S, Tabor E, Kaklamani E, Tzonou A, Stuver S, Tassopoulos N, et al. A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma. *Int J Cancer*. 1995;60:627–31.
22. Kew MC. Epidemiology of hepatocellular carcinoma. *Toxicology*. 2002;181–182:35–8.
23. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. *Lancet*. 1981;2:1129–33.
24. Arbuthnot P, Capovilla A, Kew M. Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. *J Gastroenterol Hepatol*. 2000;15:357–68.
25. Kirk GD, Bah E, Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. *Carcinogenesis*. 2006;27:2070.
26. Lee WM. Hepatitis B virus infection. *N Engl J Med*. 1997;337:1733–45.
27. Ming L, Thorgeirsson SS, Gail MH, Lu P, Harris CC, Wang N, et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. *Hepatology*. 2002;36:1214–20.
28. Lok ASF, McMahon BJ. Chronic hepatitis B. *Hepatology*. 2001;34:1225–41.
29. Kensler TW, Qian GS, Chen Jg, Groopman JD. Translational strategies for cancer prevention in liver. *Nat Rev* 2003;3:321–9.
30. Block TM, Mehta AS, Fimmel CJ, Jordon R. Molecular viral oncology of hepatocellular carcinoma. *Oncogene*. 2003;22:5093–107.
31. Ross RK, Yuan JM, Yu MC, Qian GS, Tu JT, Gao YT, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. *Lancet*. 1992;339:943–6.
32. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. *Cancer Epidemiol Biomarkers Prev*. 1994;3:3–10.
33. Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. *Int J Cancer*. 1996;67:620–5.
34. Tanaka V, Hanada K, Mizokami M, Yeo AET, Shih JWK, Gojobori T, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. *Proc Natl Acad Sci USA*. 2002;99:15584–9.
35. Kensler TW, Egner PA, Wang JB, Yr Zhu, Zhang BC, Lu PX, et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. *Gastroenterology*. 2004;127:S310–8.
36. Groopman JD, Kensler TW, Wild CP. Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. *Annu Rev Public Health*. 2008;29:187–203.
37. Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. *J Infect Public Health*. 2015:004.
38. Barth H. Hepatitis C virus: is it time to say goodbye yet? Perspectives and challenges for the next decade. *World J Hepatol*. 2015;7:725–37. doi:10.4254/wjh.v7.i5.725.
39. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. *Gastroenterology*. 2004;127:S72–8.
40. Falk H, Creech JL Jr, Heath CW Jr, Johnson MN, Key MM. Hepatic disease among workers at a vinyl chloride polymerization plant. *JAMA*. 1974;230:59–63.
41. Dragani TA, Zocchetti C. Occupational exposure to vinyl chloride and risk of hepatocellular carcinoma. *Cancer Causes Control*. 2008;19:1193.
42. Forman D, Bennett B, Stafford J, Doll R. Exposure to vinyl chloride and angiosarcoma of the liver: a report of the register of cases. *Br J Ind Med*. 1985;42:750–3.
43. Mastrangelo G, Fedeli U, Fadda E, Valentini F, Agnesi R, Magarotto G, et al. Increased risk of hepatocellular carcinoma and liver cirrhosis in vinyl chloride workers: synergistic effect of occupational exposure with alcohol intake. *Environ Health Perspect*. 2004;112:1188–92.
44. Wong RH, Chen PC, Wang JD, Du CL, Cheng TJ. Interaction of vinyl chloride monomer exposure and hepatitis B viral infection on liver cancer. *J Occup Environ Med*. 2003;45:379–83.
45. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. *Gastroenterology*. 2004;127:S87–96.

46. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology*. 2004;127:S35–50.
47. Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. *J Clin Gastroenterol*. 2007;41:761–72.
48. Pelucchi C, Gallus S, Garavito W, Bosetti C, La Vecchia C. Alcohol and tobacco use, and cancer risk for upper aerodigestive tract and liver. *Eur J Cancer Prev*. 2008;17:340–4.
49. Franceschi S, Montella M, Polesel J, La Vecchia C, Crispo A, Dal Maso L, et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. *Cancer Epidemiol Biomarkers Prev*. 2006;15:683–9.
50. Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT, et al. Tobacco and cancer: recent epidemiological evidence. *J Natl Cancer Inst*. 2004;96:99–106.
51. Giannitrapani L, Soresi M, La Spada E, Cervello M, D'Alessandro N, Montalto G. Sex hormones and risk of liver tumor. *Ann NY Acad Sci*. 2006;1089:228–36.
52. Bosch FX, Ribes J, Borrás J. Epidemiology of primary liver cancer. *Semin Liver Dis*. 1999;19:271–85.
53. Baird DT, Glasier AF. Hormonal contraception. *N Engl J Med*. 1993;328:1543–9.
54. Takamatsu S, Noguchi N, Kudoh A, Nakamura N, Kawamura T, Teramoto K, et al. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. *Hepatogastroenterology*. 2008;55:609–14.
55. Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. *Clin Gastroenterol Hepatol*. 2008;6:459–64.
56. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. *Hepatol Res*. 2007;37(Suppl 2):S88–94.
57. Khan FZ, Perumpail RB, Wong RJ, Ahmed A. Advances in hepatocellular carcinoma: nonalcoholic steatohepatitis-related hepatocellular carcinoma. *World J Hepatol*. 2015;7:2155–61. doi:10.4254/wjh.v7.i18.2155.
58. Saran U, Humar B, Kolly P, Dufour JF. Hepatocellular carcinoma and lifestyles. *J Hepatol*. 2015:028.
59. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. *Clin Liver Dis*. 2015;19:223–38. doi:10.1016/j.cld.2015.01.001 Epub Feb 26.
60. Essigmann JM, Croy RG, Nadzan AM, Busby WF Jr, Reinhold VN, Buchi G, et al. Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. *Proc Natl Acad Sci USA*. 1977;74:1870–4.
61. Sabbioni G, Skipper PL, Buchi G, Tannenbaum SR. Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. *Carcinogenesis*. 1987;8:19–24.
62. Bennett RA, Essigmann JM, Wogan GN. Excretion of an aflatoxin-guanine adduct in the urine of aflatoxin B1-treated rats. *Cancer Res*. 1981;41:650–4.
63. Groopman JD, DeMatos P, Egner PA, Love-Hunt A, Kensler TW. Molecular dosimetry of urinary aflatoxin-N7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats. *Carcinogenesis*. 1992;13:101–6.
64. Wang JS, Groopman JD. Biomarkers for carcinogen exposure: tumor initiation. Washington, DC: Taylor & Francis;1998.
65. Santella RM. Immunological methods for detection of carcinogen-DNA damage in humans. *Cancer Epidemiol Biomarkers Prev*. 1999;8:733–9.
66. Poirier MC, Santella RM, Weston A. Carcinogen macromolecular adducts and their measurement. *Carcinogenesis*. 2000;21:353–9.
67. McCoy LF, Scholl PF, Sutcliffe AE, Kieszak SM, Powers CD, Rogers HS, et al. Human aflatoxin albumin adducts quantitatively compared by ELISA, HPLC with fluorescence detection, and HPLC with isotope dilution mass spectrometry. *Cancer Epidemiol Biomarkers Prev*. 2008;17:1653–7.
68. Groopman JD, Trudel LJ, Donahue PR, Marshak-Rothstein A, Wogan GN. High-affinity monoclonal antibodies for aflatoxins and their application to solid-phase immunoassays. *Proc Natl Acad Sci USA*. 1984;81:7728–31.
69. Groopman JD, Donahue PR, Zhu JQ, Chen JS, Wogan GN. Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. *Proc Natl Acad Sci USA*. 1985;82:6492–6.
70. Egner PA, Wang JB, Yr Zhu, Zhang BC, Wu Y, Zhang QN, et al. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. *Proc Natl Acad Sci USA*. 2001;98:14601–6.
71. Groopman JD, Hasler JA, Trudel LJ, Pikul A, Donahue PR, Wogan GN. Molecular dosimetry in rat urine of aflatoxin-N7-guanine and other aflatoxin metabolites by multiple monoclonal antibody affinity chromatography and immunoaffinity/high performance liquid chromatography. *Cancer Res*. 1992;52:267–74.
72. Kensler TW, Egner PA, Davidson NE, Roebuck BD, Pikul A, Groopman JD. Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. *Cancer Res*. 1986;46:3924–31.
73. Egner PA, Gange SJ, Dolan PM, Groopman JD, Munoz A, Kensler TW. Levels of aflatoxin-albumin biomarkers in rat plasma are modulated by both long-term and transient interventions with oltipraz. *Carcinogenesis*. 1995;16:1769–73.
74. Scholl PF, McCoy L, Kensler TW, Groopman JD. Quantitative analysis and chronic dosimetry of the aflatoxin B1 plasma albumin adduct Lys-AFB1 in rats by isotope dilution mass spectrometry. *Chem Res Toxicol*. 2006;19:44–9.
75. Scholl PF, Turner PC, Sutcliffe AE, Sylla A, Diallo MS, Friesen MD, et al. Quantitative comparison of aflatoxin B1 serum albumin adducts in humans by isotope dilution mass spectrometry and ELISA. *Cancer Epidemiol Biomarkers Prev*. 2006;15:823–6.
76. Egner PA, Groopman JD, Wang JS, Kensler TW, Friesen MD. Quantification of aflatoxin-B1-N7-Guanine in human urine by high-performance liquid chromatography and isotope dilution tandem mass spectrometry. *Chem Res Toxicol*. 2006;19:1191–5.
77. Scholl PF, Groopman JD. Long-term stability of human aflatoxin B1 albumin adducts assessed by isotope dilution mass spectrometry and high-performance liquid chromatography-fluorescence. *Cancer Epidemiol Biomarkers Prev*. 2008;17:1436–9.
78. Laken SJ, Jackson PE, Kinzler KW, Vogelstein B, Strickland PT, Groopman JD, et al. Genotyping by mass spectrometric analysis of short DNA fragments. *Nat Biotechnol*. 1998;16:1352–6.
79. Jackson PE, Qian GS, Friesen MD, Zhu Yr LuP, Wang JB, et al. Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. *Cancer Res*. 2001;61:33–5.
80. Lleonart ME, Cajal SRY, Groopman JD, Friesen MD. Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. *Nucleic Acids Res*. 2004;32.
81. Lleonart ME, Kirk GD, Villar S, Lesi OA, Dasgupta A, Goedert JJ, et al. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry. *Cancer Epidemiol Biomarkers Prev*. 2005;14:2956–62.
82. Kensler TW, Egner PA, Trush MA, Bueding E, Groopman JD. Modification of aflatoxin B1 binding to DNA in vivo in rats fed

- phenolic antioxidants, ethoxyquin and a dithiothione. *Carcinogenesis*. 1985;6:759–63.
83. Roebuck BD, Liu YL, Rogers AE, Groopman JD, Kensler TW. Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. *Cancer Res*. 1991;51:5501–6.
 84. Bolton MG, Munoz A, Jacobson LP, Groopman JD, Maxuitenko YY, Roebuck BD, et al. Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. *Cancer Res*. 1993;53:3499–504.
 85. Yang EB, Cao J, Su JJ, Chow P, Schultz U, Grgacic E, et al. The tree shrews: useful animal models for the viral hepatitis and hepatocellular carcinoma. Duck hepatitis B virus: an invaluable model system for HBV infection. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. *Hepatogastroenterology*. 2005;52:613–6.
 86. Tennant BC, Toshkov IA, Peek SF, Jacob JR, Menne S, Hornbuckle WE, et al. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. *Gastroenterology*. 2004;127:S283–93.
 87. Schultz U, Grgacic E, Nassal M. Duck hepatitis B virus: an invaluable model system for HBV infection. *Adv Virus Res*. 2004;63:1–70.
 88. Chisari FV, Pinkert CA, Mulich DR, Filippi P, McLachlan A, Palmiter RD, et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. *Science*. 1985;230:1157–60.
 89. Sell S, Hunt JM, Dunsford HA, Chisari FV. Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. *Cancer Res*. 1991;51:1278–85.
 90. Kensler TW, Gange SJ, Egner PA, Dolan PM, Munoz A, Groopman JD, et al. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. *Cancer Epidemiol Biomarkers Prev*. 1997;6:603–10.
 91. Johnson NM, Egner PA, Baxter VK, Sporn MB, Wible RS, Sutter TR, et al. Complete protection against aflatoxin B1-induced liver cancer with triterpenoid: DNA adduct dosimetry, molecular signature and genotoxicity threshold. *Cancer Prev Res (Phila)*. 2014.
 92. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. *N Engl J Med*. 1997;336:1855–9.
 93. Campbell TC, Caedo JP Jr, Bulatao-Jayme J, Salamat L, Engel RW. Aflatoxin M1 in human urine. *Nature*. 1970;227:403–4.
 94. Gan LS, Skipper PL, Peng XC, Groopman JD, Chen JS, Wogan GN, et al. Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1. *Carcinogenesis*. 1988;9:1323–5.
 95. Wild CP, Hudson GJ, Sabbioni G, Chapot B, Hall AJ, Wogan GN, et al. Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia. West Africa. *Cancer Epidemiol Biomarkers Prev*. 1992;1:229–34.
 96. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. *Cancer Res*. 1994;54:4855–78.
 97. Harris CC. Multistep carcinogenesis. *Jpn J Cancer Res*. 1993;84 (inside front cover).
 98. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. *Nature*. 1991;350:427–8.
 99. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. *Nature*. 1991;350:429–31.
 100. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. *Science*. 1994;264:1317–9.
 101. Ozturk M. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. *Lancet*. 1991;338:1356–9.
 102. Foster PL, Eisenstadt E, Miller JH. Base substitution mutations induced by metabolically activated aflatoxin B1. *Proc Natl Acad Sci USA*. 1983;80:2695–8.
 103. Puisieux A, Lim S, Groopman J, Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. *Cancer Res*. 1991;51:6185–9.
 104. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. *Proc Natl Acad Sci USA*. 1993;90:8586–90.
 105. Denissenko MF, Koudriakova TB, Smith L, O'Connor TR, Riggs AD, Pfeifer GP. The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. *Oncogene*. 1998;17:3007–14.
 106. Denissenko MF, Chen JX, Tang MS, Pfeifer GP. Cytosine methylation determines hot spots of DNA damage in the human P 53 gene. *Proc Natl Acad Sci USA*. 1997;94:3893–8.
 107. Smela ME, Currier SS, Bailey EA, Essigmann JM. The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. *Carcinogenesis*. 2001;22:535–45.
 108. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. *Hepatology*. 2006;43:S173–81.
 109. Srivatanakul P, Parkin DM, Khat M, Chenvidhya D, Chotiwan P, Insiripong S, et al. Liver cancer in Thailand. II. A case-control study of hepatocellular carcinoma. *Int J Cancer*. 1991;48:329–32.
 110. Jee SH, Ohrr H, Sull JW, Samet JM. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. *J Natl Cancer Inst*. 2004;96:1851–6.
 111. Tong S, Kim KH, Chante C, Wands J, Li J. Hepatitis B Virus e Antigen Variants. *Int J Med Sci*. 2005;2:2–7.
 112. Tong S. Mechanism of HBV genome variability and replication of HBV mutants. *J Clin Virol*. 2005;34(Suppl 1):S134–8.
 113. Arbuthnot P, Kew M. Hepatitis B virus and hepatocellular carcinoma. *Int J Exp Pathol*. 2001;82:77–100.
 114. Hou J, Lau GK, Cheng J, Cheng CC, Luo K, Carman WF. T1762/A1764 variants of the basal core promoter of hepatitis B virus: serological and clinical correlations in Chinese patients. *Liver*. 1999;19:411–7.
 115. Baptista M, Kramvis A, Kew MC. High prevalence of 1762 T 1764 A mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. *Hepatology*. 1999;29:946–53.
 116. Hsia CC, Yuwen H, Tabor E. Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. *Lancet*. 1996;348:625–6.
 117. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshida M, Moriyama K, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. *J Virol*. 1994;68:8102–10.
 118. Yuen MF, Sablon E, Yuan HJ, Wong DKH, Hui CK, Wong BCY, et al. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. *Hepatology*. 2003;37:562–7.
 119. Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication

- and liver damage in East Asian hepatitis B virus carriers. *J Infect Dis.* 1999;179:775–82.
120. Cho SW, Shin YJ, Hahm KB, Jin JH, Kim YS, Kim JH, et al. Analysis of the precore and core promoter DNA sequence in liver tissues from patients with hepatocellular carcinoma. *J Korean Med Sci.* 1999;14:424–30.
 121. Yotsuyanagi H, Hino K, Tomita E, Toyoda J, Yasuda K, Iino S. Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. *J Hepatology.* 2002;37:355–63.
 122. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. *Hepatology.* 2001;34:617–24.
 123. Parekh S, Zoulim F, Ahn SH, Tsai A, Li J, Kawai S, et al. Genome replication, virion secretion and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. *J Virol.* 2003;77:6601–12.
 124. Song BC, Cui XJ, Kim HU, Cho YK. Sequential accumulation of the basal core promoter and the precore mutations in the progression of hepatitis B virus-related chronic liver disease. *Intervirology.* 2006;49:266–73.
 125. Muñoz A, Chen JG, Egner PA, Marshall ML, Johnson JL, Schneider MF, et al. Predictive power of hepatitis B 1762T/1764A mutations in plasma for hepatocellular carcinoma risk in Qidong, China. *Carcinogenesis.* 2011;32:860–5.
 126. Kensler TW, Groopman JD, Wogan GN. Use of carcinogen-DNA and carcinogen-protein adduct biomarkers for cohort selection and as modifiable end points in chemoprevention trials. *IARC Sci Publ.* 1996;237–48.
 127. Turner PC, Sylla A, Gong YY, Sutcliffe AE, Hall AJ, Wild CP. Reduction in exposure to carcinogenic aflatoxin by postharvest intervention measures in west Africa: a community-based intervention study. *Lancet.* 2005;365:1950–6.
 128. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: Isolation and elucidation of structure. *Proc Natl Acad Sci USA.* 1992;89:2399–403.
 129. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. *Annu Rev Pharmacol Toxicol.* 2006;47:89.
 130. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. *Proc Natl Acad Sci USA.* 2001;98:3410–5.
 131. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of *Helicobacter pylori* and prevents benzo[a]pyrene-induced stomach tumors. *Proc Natl Acad Sci USA.* 2002;99:7610–5.
 132. Jirousek L. Über das vorkommen von trithionen (1,2-dithiocyclopent-4-en-3-thione) in Brassicapflanzen. *Naturwissenschaften.* 1958;45:386–7.
 133. Marks SH. Analysis of a reported organosulfur, carcinogenesis inhibitor: 1,2-dithiole-3-thione in cabbage. *J Agric Food Chem.* 1991;39:893–5.
 134. Kensler TW, Groopman JD, Sutter TR, Curphey TJ, Roebuck BD. Development of cancer chemopreventive agents: oltipraz as a paradigm. *Chem Res Toxicol.* 1999;12:113–26.
 135. Kensler TW, He X, Otieno M, Egner PA, Jacobson LP, Chen B, et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. *Cancer Epidemiol Biomarkers Prev.* 1998;7:127–34.
 136. Wang JS, Shen X, He X, Yr Zhu, Zhang BC, Wang JB, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B 1 by Oltipraz in residents of Qidong, People's Republic of China. *J Natl Cancer Inst.* 1999;91:347–54.
 137. Dinkova-Kostova AT, Fahey JW, Wade KL, Jenkins SN, Shapito TA, Fuchs EJ, et al. Induction of the phase 2 response in mouse and human skin by sulforaphane-containing broccoli sprout extracts. *Cancer Epidemiol Biomarkers Prev.* 2007;16:847–51.
 138. Talalay P, Fahey JW. Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. *J Nutr.* 2001;131:3027S–33S.
 139. Fahey JW, Kensler TW. Role of dietary supplements/nutraceuticals in chemoprevention through induction of cytoprotective enzymes. *Chem Res Toxicol.* 2007;20:572–6.
 140. Kensler TW, Chen JG, Egner PA, Fahey JW, Jacobson LP, Stephenson KK, et al. Broccoli sprout modulation of the urinary excretion of Aflatoxin, DNA adducts and phenanthrene tetraols in a randomized clinical trial in Qidong, People's Republic of China. *J Nutr.* 2005;135:3051S–S.
 141. Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. *Nutr Rev.* 2004;62:204–11.
 142. Yang CS, Lambert JD, Hou Z, Ju J, Lu G, Hao X. Molecular targets for the cancer preventive activity of tea polyphenols. *Mol Carcinog.* 2006;45:431–5.
 143. Qin G, Gopalan-Kriczky P, Su J, Ning Y, Lotlikar PD. Inhibition of aflatoxin B1-induced initiation of hepatocarcinogenesis in the rat by green tea. *Cancer Lett.* 1997;112:149–54.
 144. Luo H, Tang L, Tang M, Billam M, Huang T, Yu J, et al. Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine. *Carcinogenesis.* 2006;27:262–8.
 145. Tang L, Tang M, Xu L, Luo H, Huang T, Yu J, et al. Modulation of aflatoxin biomarkers in human blood and urine by green tea polyphenols intervention. *Carcinogenesis.* 2008;29:411–7.
 146. Wong IHN, Lo YMD, Lai PBS, Johnson PJ. Relationship of p56 methylation status and serum α -fetoprotein concentration in hepatocellular carcinoma patients. *Clin Chem.* 2003;46:1420–2.
 147. Chen JG, Parkin DM, Chen QG, Shen QJ, Zhang BC, Zhu YR. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. *J Med Screen.* 2003;10:204–9.
 148. Wong IHN, Lo YMD, Zhang J, Liew CT, Ng MHL, Wong N, et al. Detection of Aberrant p16 methylation in the plasma and serum of liver cancer patients. *Cancer Res.* 1999;59:71–3.
 149. Wong N, Lai P, Pang E, Fung LF, Sheng Z, Wong V, et al. Genomic aberrations in human hepatocellular carcinomas of differing etiologies. *Clin Cancer Res.* 2000;6:4000–9.
 150. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, et al. DNA methylation and environmental exposure in human hepatocellular carcinoma. *J Natl Cancer Inst.* 2002;94:755–61.
 151. Kirk GD, Lesi OA, Mendy M, Szymanska K, Whittle H, Goedert JJ, et al. 249 ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. *Oncogene.* 2005;24:5858–67.
 152. Sidransky D. Emerging molecular markers of cancer. *Nature.* 2002;2:210–9.
 153. Jen J, Wu L, Sidransky D. An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. *Ann N Y Acad Sci.* 2000;906:8–12.
 154. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. *Cancer Metastasis Rev.* 1999;18:65–73.
 155. Sidransky D, Hollstein M. Clinical implications of the p53 gene. *Annu Rev Med.* 1996;47:285–301.

156. Kirk GD, Camus-Randon AM, Mendy M, Goedert JJ, Merle P, Trepo C, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. *J Natl Cancer Inst.* 2000;92:148–53.
157. Jackson PE, Kuang SY, Wang JB, Strickland PT, Munoz A, Kensler TW, et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. *Carcinogenesis.* 2003;24:1657–63.
158. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. *Nat Genet.* 2002;31:339–46.
159. Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. *Hepatology.* 2006;43:S145–50.
160. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. *Nat Genet.* 2015;47:505–11.
161. Chen JG, Egner PA, Ng D, Jacobson LP, Munoz A, Zhu Y-R, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. *Cancer Prev Res.* 2013;6:1038–45.
162. Groopman JD, Egner PA, Schulze KJ, Wu LS, Merrill R, Mehra S, et al. Aflatoxin exposure during the first 1000 days of life in rural South Asia assessed by aflatoxin B1-lysine albumin biomarkers. *Food Chem Toxicol.* 2014;74:184–9.
163. Strosnider H, Azziz-Baumgartner E, Banziger M, Bhat RV, Breiman R, Brune MN, et al. Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries. *Environ Health Perspect.* 2006;114:1898–903.
164. Cupid BC, Lightfoot TJ, Russell D, Gant SJ, Turner PC, Dingley KH, et al. The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure. *Food Chem Toxicol.* 2004;42:559–69.
165. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002, Cancer incidence, mortality and prevalence worldwide, IARC cancer base No. 5, version 2.0. Lyon: IARC Press; 2004.

Hepatocellular Carcinoma

Diagnosis and Treatment

Carr, B.I. (Ed.)

2016, XXI, 596 p. 129 illus., 80 illus. in color., Hardcover

ISBN: 978-3-319-34212-2